Stockscreener 앱 받기
198.05
0.41%
-0.81
시간 외 거래:
198.37
0.32
+0.16%
전일 마감가:
$198.86
열려 있는:
$199.08
하루 거래량:
4.10M
Relative Volume:
0.67
시가총액:
$349.84B
수익:
$58.33B
순이익/손실:
$3.76B
주가수익비율:
94.31
EPS:
2.1
순현금흐름:
$18.24B
1주 성능:
+1.45%
1개월 성능:
+4.36%
6개월 성능:
+3.91%
1년 성능:
+4.02%
1일 변동 폭
$197.14
$200.33
1주일 범위
$193.72
$200.33
52주 변동 폭
$163.81
$218.66
애브비 Stock (ABBV) Company Profile
명칭
Abbvie Inc
전화
(847) 932-7900
주소
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
ABBV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
198.05 | 346.78B | 58.33B | 3.76B | 18.24B | 2.10 |
|
LLY
Lilly Eli Co
|
625.65 | 670.04B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
173.33 | 410.84B | 90.63B | 22.66B | 16.40B | 9.35 |
|
NVS
Novartis Ag Adr
|
116.84 | 219.72B | 55.19B | 13.65B | 16.81B | 6.86 |
|
MRK
Merck Co Inc
|
80.69 | 198.42B | 63.62B | 16.41B | 14.72B | 6.49 |
애브비 Stock (ABBV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-12-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-04 | 업그레이드 | Argus | Hold → Buy |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-06-05 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-05-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-01-29 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-12-11 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-30 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-09-29 | 개시 | Raymond James | Outperform |
| 2023-07-25 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-04-05 | 다운그레이드 | Argus | Buy → Hold |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2023-02-22 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | 업그레이드 | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-11-08 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Underperform |
| 2022-05-06 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-02-28 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-03 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-03 | 재확인 | Barclays | Equal Weight |
| 2022-02-03 | 재확인 | BofA Securities | Neutral |
| 2022-02-03 | 재확인 | Goldman | Neutral |
| 2022-01-13 | 개시 | Redburn | Buy |
| 2022-01-12 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-09 | 재개 | Wells Fargo | Overweight |
| 2021-11-23 | 업그레이드 | Societe Generale | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2020-11-10 | 재개 | Bernstein | Outperform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-23 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | 업그레이드 | Argus | Hold → Buy |
| 2020-05-18 | 재개 | BofA/Merrill | Neutral |
| 2020-05-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-05-11 | 재개 | Morgan Stanley | Overweight |
| 2020-04-20 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | 재확인 | Cowen | Outperform |
| 2019-09-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-08-20 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | 개시 | Goldman | Neutral |
| 2019-04-29 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
모두보기
애브비 주식(ABBV)의 최신 뉴스
AbbVie’s Drug Upadacitinib Shows Positive Phase 3 Results for Severe Alopecia Areata Treatment - Insider Monkey
AbbVie Secures FDA Approval to Expand Mavyret’s Label - MSN
AbbVie’s Upcoming Study on ABBV-932: What Investors Need to Know - TipRanks
AbbVie's $0.81B Volume Ranks 104th as Stock Falls 0.41% on Mixed Earnings and Analyst Upgrades - AInvest
AbbVie-Genmab cancer collab shows promising results - Crain's Chicago Business
Genmab/AbbVie’s Epkinly Likely To See Label Expansion After Phase III Win - insights.citeline.com
AbbVie Inc. (ABBV): A Bull Case Theory - MSN
AbbVie Inclusion In Medicare Drug Talks Fails To Justify Lawsuit, Court Rules - Benzinga
Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79% - Benzinga
AbbVie and Genmab’s Promising B-Cell Lymphoma Trial: A Potential Game-Changer? - The Globe and Mail
AbbVie and Genmab’s Promising Phase 3 Trial for Follicular Lymphoma - The Globe and Mail
AbbVie’s Immunotherapy Trial: A Potential Game-Changer for Advanced Solid Tumors - TipRanks
AbbVie’s Duodopa Study: A Deep Dive into Parkinson’s Treatment - TipRanks
AbbVie Advances Glaucoma Treatment with XEN63 Gel Stent Study - TipRanks
AbbVie’s Promising Phase 3 Study on Upadacitinib for Hidradenitis Suppurativa - TipRanks
AbbVie’s Skyrizi rises to the top for pharma TV ad impressions - Medical Marketing and Media
AbbVie’s upadacitinib holds potential to cement dominant place in alopecia areata - The Pharma Letter
Pfizer and AbbVie Collaborate on Promising Pediatric Antibiotic Study - TipRanks
AbbVie’s Top Executive Makes a Multi-Million Dollar Stock Sale - TipRanks
AbbVie’s Phase 3 Study on Lutikizumab: A Potential Game-Changer for Hidradenitis Suppurativa - TipRanks
AbbVie and Genmab’s Epcoritamab Trial: A Promising Update for B-Cell Lymphoma Treatment - TipRanks
AbbVie’s Promising Study on Etentamig for Multiple Myeloma: A Potential Game-Changer - TipRanks
XtalPi inks pact with Greg Verdine’s DoveTree; Regenxbio, AbbVie update deal - Endpoints News
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Castle Biosciences (CSTL) and Regeneron (REGN) - The Globe and Mail
United States Pharmaceutical Market Forecast and Company Analysis Report 2025-2033 Featuring F. Hoffmann-La Roche, Novartis, Abbvie, Johnson & Johnson, Merck, Pfizer, BMS, Sanofi, GSK, Takeda - Yahoo Finance
Saudi Arabia OTC Artificial Tears Market Forecast and - GlobeNewswire
Saudi Arabia OTC Artificial Tears Market Forecast and Company Analysis Report 2025-2033 Featuring AbbVie, Akorn, Alcon, Bausch Health, J&J, Nicox, Novartis, Santen Pharmaceutical, Sun Pharmaceutical - Yahoo Finance
RegenXBio and AbbVie Amend Collaboration Agreement - TipRanks
Analyst recommendations: Abbvie, Airbnb, AMD, Ebay, Disney… - MarketScreener
AbbVie's 123rd-Ranked $790M Trading Volume Contrasts with $2.1B Acquisition and $1.9B Licensing Deals in Oncology Expansion - AInvest
AbbVie and Genmab’s Promising Phase 3 Study for DLBCL Treatment - The Globe and Mail
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know - sharewise.com
AbbVie Stock Climbs 0.69% on $820M Volume Ranked 114th as Profits Plunge 31% Amid Resilient Revenue Growth - AInvest
AbbVie’s Ubrogepant Study: A New Hope for Menstrual Migraine Relief - TipRanks
AbbVie’s ABBV-101 Study: Promising Developments in B-Cell Malignancy Treatment - TipRanks
AbbVie and Genmab’s Promising Phase 2 Trial for DLBCL Treatment - TipRanks
AbbVie and Genmab’s Promising New Approach to Follicular Lymphoma - TipRanks
AbbVie Stock Outlook: Is Wall Street Bullish or Bearish? - MSN
AbbVie Stock Outlook: Is Wall Street Bullish Or Bearish? - Barchart.com
AbbVie Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
AbbVie price readies to tackle important resistanceForecast today05-08-2025 - Economies.com
Allergan Aesthetics Unveils the New Faces of Natrelle® and Real Stories of Empowerment and Transparency - AbbVie News Center
Stock Analysis | Abbvie OutlookA Mixed Picture with Strong Fundamentals and Optimistic Analysts - AInvest
AbbVie (ABBV) Q2 2025 Earnings Call Transcript - Mitrade
AbbVie: Balancing Strong Earnings with Humira Challenges and External Risks - TipRanks
AbbVie Inc. stock rises Monday, still underperforms market - MarketWatch
AbbVie Inc. SEC 10-Q Report - TradingView
Layoff Tracker: Sirona Liquidates TFChem, Merck Will Cut 6,000 Employees - BioSpace
AbbVie’s Promising Study on ABBV-453 for Multiple Myeloma: A Potential Game-Changer - TipRanks
AbbVie Raises 2025 Outlook After Q2 Beat - The Motley Fool
AbbVie Raises 2025 Outlook After Q2 Beat - The Globe and Mail
애브비 (ABBV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.05%
자본화:
|
볼륨(24시간):